A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1155-1161

  Wang, Yan ^a   Yu, Yi Yi ^a   Li, Wei ^a   Feng, Yi ^a   Hou, Jun ^a   Ji, Yuan ^a   Sun, Yi Hong ^a   Shen, Kun Tang ^a   Shen, Zhen Bin ^a   Qin, Xin Yu ^a   Liu, Tian Shu ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Gastric cancer; Para aortic lymph node

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LUNG INFECTION; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS;

EID: 84903817520     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2449-1     Document Type: Article

References (23)

1. Forman D, Burley VJ (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20(4):633-639
2. Baba M, Hokita S, Natsugoe S et al (2000) Paraaortic lymphadenectomy in patients with advanced carcinoma of the upper third of the stomach. Hepatogastroenterology 47(33):893-896 (Pubitemid 30417319)
3. Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14(2):101-112
4. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471
5. Sasako M, Sano T, Yamamoto S et al (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359(5):453-462
6. Park IH, Kim SY, Kim YW et al (2011) Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol 67(1):127-136
7. Cunningham D, Allum WH, Stenning SP et al (2006) MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11-20
8. Nakajima T, Ota K, Ishihara S et al (1997) Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4(3):203-208 (Pubitemid 127725245)
9. Yonemura Y, Sawa T, Kinoshita K et al (1993) Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17(2):256-262 (Pubitemid 23120858)
10. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
11. Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521-1530 (Pubitemid 37151509)
12. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176-181 (Pubitemid 36962641)
13. Som PM (1992) Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. AJR Am J Roentgenol 158(5):771-773
14. Marcus SG, Cohen D, Lin K et al (2003) Complication of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg 7(8):1015-1023 (Pubitemid 37524069)
15. Schuhmacher C, Gretschel S, Lordick F et al (2010) Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28(35):5210-5218
16. Liao Y, Yang ZL, Peng JS, Xiang J, Wang JP (2013) Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. J Gastroenterol Hepatol 28(5):777-782
17. Lowy AM, Mansfield PF, Leach SD et al (1999) Response to neo-adjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229(3):303-308 (Pubitemid 30191763)
18. Hartgrink HH, van de Velde CJ, Putter H et al (2004) Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomized FAMTX trial Include. Eur J Surg Oncol 30(6):643-649 (Pubitemid 39060735)
19. Nio Y, Koike M, Omori H et al (2004) A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-a single institute study. Anticancer Res 24(3b):1879-1887 (Pubitemid 38954602)
20. Luo HY, Xu RH, Wang F et al (2010) Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 56(2):94-100
21. Cunningham D, Okines AF, Ashley S (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36-46
22. Van Meerten E, Eskens FA, Van Gameren EC, Van Der Gaast A (2007) First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer 96(9):1348-1352 (Pubitemid 46685802)
23. Liu C, Sun Q, Hang X, Zhong B, Wang D (2008) Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anticancer Drugs 19(8):825-831